University of California, Los Angeles
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).
University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.
University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.
Top-decile sponsor footprint
University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
897 total, page 3 of 18
Spinal Cord Stimulation to Shorten Ventilator Dependence in ARDS Patients
NCT05928052
Sinus Disease in Young Children With Cystic Fibrosis
NCT06191640
UCLA REST Study (REsearch on Sleep Techniques)
NCT05576090
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
NCT05516277
Writing About Experiences and Health in Older Adults II
NCT05524597
Pain and Major Depressive Disorder
NCT04556890
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
NCT05419726
Use of Continuous Glucose Monitors in Children and Adolescents With Obesity
NCT06254768
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
NCT05846282
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector
NCT05432310
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
NCT05525507
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
NCT05452031
SAFETY-A for Promoting Equity in Suicide Prevention Outcomes in Schools
NCT05834660
Transvaginal Electrical Stimulation for Myofascial Pelvic Pain
NCT05354869
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT05190978
Evaluating tDCS Brain-stimulation in Depression Using MRI
NCT05598034
Safe Treatment for Emergency Presentation for Suicidal Ideation and Behavior in Youth
NCT05304065
Social Facilitation of Emotion Regulation in Adolescence
NCT06458920
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
NCT05518305
Efficacy of Trigeminal Nerve Stimulation for ADHD
NCT05374187
Expression of Stress Markers During Meth Treatment (EXPRESS+)
NCT05558345
Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease
NCT05417555
S.T.A.N.D. Alacrity Center Signature Project
NCT05591937
COVID-19 Outcome Prediction Algorithm
NCT05471011
Decoding and Selective Modulation of Human Memory During Awake/Sleep Cycles
NCT05452122
Children's Bipolar Network Treatment Trial I
NCT05427123
Ferric Citrate and Chronic Kidney Disease in Children
NCT04741646
Kind Minds Program for Youth With Anxiety and Depression
NCT05353751
Socially Assistive Robots to Enhance Magnification Device Use for Reading
NCT04190134
Quadratus Lumborum Block for Total Hip Arthroplasty
NCT05247255
Social Support and Reduced Fear Acquisition
NCT04564976
DETERMINE: Detemir vs NPH
NCT05124457
Social Support and Enhanced Fear Extinction
NCT04565041
Secretin in Refeeding
NCT05235867
Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW
NCT05018611
FAPI PET for Lung Fibrosis
NCT05365802
Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury
NCT04883463
Biologic Therapy to Prevent Osteoarthritis After ACL Injury
NCT03968913
Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients
NCT04997473
Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)
NCT04557891
Cannabis Effects as a Function of Sex
NCT04385082
CBT for Youth With Autism and Emotional/Behavioral Needs in Community Care Settings
NCT05031364
Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol
NCT04661683
DBS of the SCC for the Treatment of Medically Refractory CLBP
NCT04085406
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
NCT04354545
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
NCT04558164
Brain Imaging Biomarkers for Response to Spinal Cord Stimulation in Patients With Chronic Low Back Pain
NCT04658628
Neural Correlates of Real World Spatial Navigation in Humans
NCT04874220
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
NCT04469439
SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke
NCT03737786
What is open in the University of California, Los Angeles pipeline
158 recruiting of 897 indexed (18% open); 622 completed (69%).
Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).
Top condition: Depression (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, Los Angeles: open-pipeline peers nationwide
Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 897 trials (± recruiting share)
- Indiana University · 890 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- ConvaTec · 18% recruiting · 17 trials
- Endologix · 18% recruiting · 17 trials
- National Institute on Deafness and Other Communication Disorders (NIDCD) · 18% recruiting · 34 trials
- NICHD Pelvic Floor Disorders Network · 18% recruiting · 17 trials
Related
What to do with this University of California, Los Angeles page
897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.
- 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, Los Angeles pipeline card: 897 registered trials from official public datasets.Report a data error.